Transmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor function

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10281-10292

  Scheideman, Elizabeth H ^a   Marlatt, Sara A ^a   Xie, Yanhua ^a   Hu, Yani ^a   Sutton, Richard E ^a,b   Dimaio, Daniel ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; MARAVIROC; MUTANT PROTEIN; R5 TROPIC GLYCOPROTEIN GP 120; TRANSMEMBRANE PROTEIN APTAMER; UNCLASSIFIED DRUG; X4 TROPIC GLYCOPROTEIN GP 120;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIVIRAL RESISTANCE; ARTICLE; CELL SURFACE; GENETIC TRANSDUCTION; HIV REPORTER VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PSEUDOTYPING; T LYMPHOCYTE; VIRAL TROPISM; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; BIOTINYLATION; CELL LINE; CELL MEMBRANE; CHEMOKINES; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, VIRAL; GENE LIBRARY; HEK293 CELLS; HIV INFECTIONS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 84869046474     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00910-12     Document Type: Article

References (44)

1. An DS, et al. 2007. Stable reduction of CCR5 by RNAi through hemato- poietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. U. S. A. 104:13110-13115.
2. Anderson J, Akkina R. 2007. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 14:1287-1297.
3. + hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol. Ther. 1:244-254.
4. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
5. Billick E, et al. 2004. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodefi- ciency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 78:4134-4144.
6. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mamma- lian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90:8033-8037.
7. Cammett TJ, et al. 2010. Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. Proc. Natl. Acad. Sci. U. S. A. 107:3447-3452.
8. Charo IF, et al. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 91:2752-2756.
9. Contento RL, et al. 2008. CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. U. S. A. 105:10101-10106.
10. Coskun AK, van Maanen M, Nguyen V, Sutton RE. 2006. Human chromosome 2 carries a gene required for production of infectious human immunodeficiency virus type 1. J. Virol. 80:3406-3415.
11. Doms RW, Peiper SC. 1997. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235:179-190.
12. Doranz BJ, et al. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2β as fusion cofactors. Cell 85:1149-1158.
13. Freeman-Cook LL, DiMaio D. 2005. Modulation of cell function by small transmembrane proteins modeled on the bovine papillomavirus E5 pro- tein. Oncogene 24:7756-7762.
14. Freeman-Cook LL, et al. 2004. Selection and characterization of small random transmembrane proteins that bind and activate the platelet- derived growth factor β receptor. J. Mol. Biol. 338:907-920.
15. Garcia-Perez J, et al. 2011. An allosteric model of maraviroc binding to CCR5. J. Biol. Chem. 286:33409-33421.
16. George SR, et al. 1998. A transmembrane domain-derived peptide inhib- its D1 dopamine receptor function without affecting receptor oligomer- ization. J. Biol. Chem. 273:30244-30248.
17. Gulick RM, et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
18. + cells with HIV-1-derived lentiviral vectors. Mol. Ther. 2:71-80.
19. Hebert TE, et al. 1996. A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activa- tion. J. Biol. Chem. 271:16384-16392.
20. Holt N, et al. 2010. Human hematopoietic stem/progenitor cells modi- fied by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28:839-847.
21. Hütter G, et al. 2009. Long-term control of HIV by CCR5 Delta32/ Delta32 stem-cell transplantation. N. Engl. J. Med. 360:692-698.
22. Isik N, Hereld D, Jin T. 2008. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS One 3:e3424. doi:10.1371/ journal.pone.0003424.
23. Ji TH, Grossman M, Ji I. 1998. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J. Biol. Chem. 273:17299-17302.
24. Kondru R, et al. 2008. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73:789-800.
25. Kuhmann SE, Hartley O. 2008. Targeting chemokine receptors in HIV: a status report. Annu. Rev. Pharmacol. Toxicol. 48:425-461.
26. Labrecque J, et al. 2011. HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay. Virology 413:231-243.
27. Lee B, et al. 1999. Epitope mapping of CCR5 reveals multiple conforma- tional states and distinct but overlapping structures involved in chemo- kine and coreceptor function. J. Biol. Chem. 274:9617-9626.
28. Li W, Yu M, Bai L, Bu D, Xu X. 2006. Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells. J. Acquir. Immune Defic. Syndr. 43:516-522.
29. Liu R, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
30. Mansky LM. 2002. HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist. Updat. 5:219-223.
31. Marlatt SA, et al. 2011. Construction and maintenance of randomized retroviral expression libraries for transmembrane protein engineering. Protein Eng. Des. Sel. 24:311-320.
32. Moore JP, Kuritzkes DR. 2009. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118-124.
33. Naviaux RK, Costanzi E, Haas M, Verma I. 1996. The pCL vector system: rapid production of helper-free, high titer, recombinant retrovi- ruses. J. Virol. 70:5701-5705.
34. Rana S, et al. 1997. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodefi- ciency virus: resistance to patient-derived and prototype isolates resulting from the δ mutation. J. Virol. 71:3219-3227.
35. Rucker J, et al. 1996. Regions in β-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87:437-446.
36. Samson M, et al. 1996. Resistance to HIV-1 infection in caucasian indi- viduals bearing mutant alleles of the CCR5-chemokine receptor gene. Na- ture 382:722-725.
37. Sattentau QJ, Weiss RA. 1988. The CD4 antigen: physiological ligand and HIV receptor. Cell 52:631-633.
38. Schleifman EB, et al. 2011. Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem. Biol. 18:1189-1198.
39. Shimizu S, et al. 2010. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu- BLT mouse model. Blood 115:1534-1544.
40. Talbert-Slagle K, DiMaio D. 2009. The bovine papillomavirus E5 protein and the PDGF β receptor: it takes two to tango. Virology 384:345-351.
41. Tarasova NI, Rice WG, Michejda CJ. 1999. Inhibition of G-protein- coupled receptor function by disruption of transmembrane domain inter- actions. J. Biol. Chem. 274:34911-34915.
42. Tilton JC, et al. 2010. A maraviroc-resistant HIV-1 with narrow cross- resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863-10876.
43. van't Wout AB, et al. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and ver- tical transmission. J. Clin. Invest. 94:2060-2067.
44. Yee JK, et al. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepato- cytes. Proc. Natl. Acad. Sci. U. S. A. 91:9564-9568.